Search
for
Sort by
Research
540-570 / 1000+ resultsresearch Rational Design and Synthesis of 4-((1R,2R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
research Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Antiandrogenic activity of Riboflavin 5′-phosphate (FMN) in 22Rv1 and LNCaP human prostate cancer cell lines
Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.
research Isotretinoin-induced hair growth in a case of hereditary hypotrichosis simplex of the scalp: A promising therapeutic approach
Isotretinoin may effectively treat hereditary hypotrichosis simplex, a rare hair loss condition.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Metabolic effects of 5α-reductase inhibition in humans
Dutasteride may reduce insulin sensitivity and increase body fat.
research Development of Liposomal Systems of Finasteride for Topical Applications: Design, Characterization, and In Vitro Evaluation
Liposomes improve finasteride delivery for hair loss treatment, making it a promising option for topical use.
research Drug Breakdown: FINASTERIDE
research Louisiana Marinas and Boat Launches, LOSCO (2003) [marinas]
Finasteride, selenium, and vitamin E may help prevent prostate cancer.
research PROTACs: A novel strategy for cancer drug discovery and development
PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Potencial de nanopartículas poliméricas de Delonix contendo isotretinoína para o tratamento da acne
Delonix polymeric nanoparticles with isotretinoin effectively treat acne by targeting hair follicles and reducing skin irritation.
research Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists
Hormonal therapies effectively treat acne and improve quality of life.
research Clinical assessment of CL22209, a standardized proprietary extract of <i>Asparagus racemosus</i>, for mitigating vasomotor and menstrual symptoms in perimenopausal women: A randomized, double-blind, placebo-controlled study
CL22209, an Asparagus racemosus extract, safely reduces perimenopausal symptoms and balances hormones.
research A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia
IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
research Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is effective long-term for treating alopecia areata in teens.
research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-α-Reductase in the Treatment of Androgenetic Alopecia
Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research Validated LC-MS/MS Method for Simultaneous Quantification of Finasteride in Human Plasma
research Lung Cancer Chemoprevention with Retinol Palmitate: Preliminary data from a randomized trial on stage la non small-cell lung cancer
Retinol palmitate may reduce cancer relapses in early-stage lung cancer patients.
research Minerva
Minoxidil is better for female hair loss without hormonal issues, cyproterone acetate for those with; people with treated congenital heart disease have lower life quality; personality differs in types of infertility; oral terbinafine is best for toenail fungus; bladder training reduces incontinence; nurse clinics help with heart disease; weight loss improves body composition and liver disease; computer training cuts drug errors.
research The Long-Term Effect Of Specific Type II 5??-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial
research Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
research Clascoterone: First Approval
Clascoterone cream was approved in the USA for treating acne in people aged 12 and older.
research Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line
Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
research Buy Kerablak Calcium Pantothenate Tablet – Online Generic Medicine
research Buy Kerablak Calcium Pantothenate Tablet – Online Generic Medicine
research Novel drugs of United States Food and Drug Administration approved in 2024
In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.